You need to be logged in to continue.
Please Login or Register

Activity Release Date: January 12, 2010
Activity Expiration Date: January 12, 2011

Program Overview

Physicians who treat patients with hematologic malignancies must remain familiar with the most current treatments. Hematologic malignancies are far from uncommon. Of the estimated 1,479,350 new cases and 562,340 deaths from all cancers anticipated in 2009 in the United States, 145,540 (10%) were expected to be new cases of hematologic malignancies (leukemia, lymphoma, and myeloma) with 59,850 (10.6%) associated deaths.

Hematology-oncology physicians have been required to translate into practice almost twice as much clinical study data than their predecessors did a decade earlier. Numerous trials are underway or recently completed examining novel therapies used sequentially and in new combinations with the goal of improving response rates and ultimately survival.

This continuing education activity features summaries from the ASH 2009 meeting in New Orleans regarding the ASH/ASCO joint symposium and selected advanced phase clinical trial reports for leukemia, non-Hodgkin’s lymphoma, and multiple myeloma. The ASH/ASCO joint symposium was a review of what peers judged to be among some of the best science from the 2009 ASCO Annual Meeting. The summaries are reported by Eric Dean, MD, a hematology/oncology fellow of the University of California, San Francisco, who attended the meeting, and are written for the interests of community practitioners who treat hematologic malignancies in their patients in order to keep them abreast of the most current clinical study findings.

Learning Objectives

At the conclusion of this educational activity, participants should be able to:

1. Cite and interpret advances highlighted in the ASH/ASCO 2009 joint symposium regarding leukemia, lymphoma, and multiple myeloma
2. Recall and describe select late phase clinical studies presented at ASH 2009, including late-breaking submissions regarding leukemia, lymphoma, and multiple myeloma
3. Identify key endpoints in the select late phase clinical studies presented at ASH 2009

Intended Audience

This activity is designed for community physicians interested in learning more about advances in hematologic malignancies, including leukemia, lymphoma and multiple myeloma, and the management of these patients.

Instructions for Participation

This activity is designed to be completed within the designated time period. To successfully earn credit, participants must read all seven modules. There are no fees for participating in this activity. All participants must complete the Activity Evaluation Form. Participants must receive a minimum score of 70% on the self-assessment portion of the form to qualify for CME credit. Certificates may be printed immediately after the successful completion of the self-assessment form.

Faculty

Eric Dean, MD
Department of Medicine
Institute for Human Genetics
Medical Effectiveness Research Center
and Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Dr. Eric Dean received his medical degree from Harvard Medical School, Boston, Massachusetts. He continued his postdoctoral training at the University of California, San Francisco (UCSF) with an internal medicine residency and a hematology/oncology fellowship.

Dr. Dean is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society of Human Genetics. He is presently involved in a genome-wide association study to identify single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) associated with multiple myeloma, and the identification of associations between clinical outcomes and identified risk SNPs at UCSF Institute for Human Genetics Medical Effectiveness Research Center and Helen Diller Family Comprehensive Cancer Center.

Accreditation

CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), ACPE and California Board of Nursing, MediCom Worldwide, Inc. requires that all program planners, faculty, and providers who are in a position to control the content of a CE activity are required to disclose any relevant financial relationships they may have or have had within the last 12 months with the commercial supporter or the manufacturer(s) of any commercial device(s) discussed in this educational activity. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Eric Dean has disclosed that he has no significant relationships with the grantor or any other commercial company whose products and services may be related to his presentation.

Provider Disclosures

The indivuduals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, executive director; Jacqui Brooks, MBBCh, MRCPsych, VP medical education; and Gene Tombler, PhD, medical director-oncology have nothing to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Dean indicated that his presentation would not include the discussion of unlabeled uses of commercial products or investigational/unapproved products not yet approved by the FDA for any use in the United States.

Conflict of Interest Resolution

To resolve identified conflicts of interest, the educational content was fully peer reviewed by members of the MediCom Content Review Committee. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.

Americans with Disabilities Act/Special Needs

MediCom Worldwide, Inc. is committed to equality of educational opportunity and does not discriminate against applicants, students, or employees on the basis of race, color, religion, sex, national origin, age, disability, veterans status, or sexual orientation.

Hardware/Software Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft®Silverlight™.

Supported by an independent educational grant from Cephalon Oncology.

©2010 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067.

No portion of this material may be copied or duplicated without the expressed permission of MediCom.

You need to be logged in to continue.
Please Login or Register